Ad is loading...
DNLI
Price
$24.22
Change
-$0.20 (-0.82%)
Updated
Nov 21 closing price
101 days until earnings call
PGEN
Price
$0.90
Change
+$0.06 (+7.14%)
Updated
Nov 21 closing price
96 days until earnings call
Ad is loading...

DNLI vs PGEN

Header iconDNLI vs PGEN Comparison
Open Charts DNLI vs PGENBanner chart's image
Denali Therapeutics
Price$24.22
Change-$0.20 (-0.82%)
Volume$1.48M
CapitalizationN/A
Precigen
Price$0.90
Change+$0.06 (+7.14%)
Volume$795.76K
CapitalizationN/A
DNLI vs PGEN Comparison Chart
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
DNLI vs. PGEN commentary
Nov 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a StrongSell and PGEN is a StrongSell.

COMPARISON
Comparison
Nov 22, 2024
Stock price -- (DNLI: $24.22 vs. PGEN: $0.90)
Brand notoriety: DNLI and PGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 177% vs. PGEN: 103%
Market capitalization -- DNLI: $3.51B vs. PGEN: $264.43M
DNLI [@Biotechnology] is valued at $3.51B. PGEN’s [@Biotechnology] market capitalization is $264.43M. The market cap for tickers in the [@Biotechnology] industry ranges from $463.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whilePGEN’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • PGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, DNLI is a better buy in the long-term than PGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 3 TA indicator(s) are bullish while PGEN’s TA Score has 3 bullish TA indicator(s).

  • DNLI’s TA Score: 3 bullish, 7 bearish.
  • PGEN’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, PGEN is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а -14.87% price change this week, while PGEN (@Biotechnology) price change was +2.27% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.74%. For the same industry, the average monthly price growth was -7.78%, and the average quarterly price growth was +1.53%.

Reported Earning Dates

DNLI is expected to report earnings on Mar 03, 2025.

PGEN is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Biotechnology (-3.74% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($3.52B) has a higher market cap than PGEN($264M). DNLI YTD gains are higher at: 12.861 vs. PGEN (-32.619). PGEN has higher annual earnings (EBITDA): -136.11M vs. DNLI (-496.05M). DNLI has more cash in the bank: 837M vs. PGEN (28.6M). PGEN has less debt than DNLI: PGEN (5.75M) vs DNLI (52.5M). PGEN has higher revenues than DNLI: PGEN (3.96M) vs DNLI (0).
DNLIPGENDNLI / PGEN
Capitalization3.52B264M1,331%
EBITDA-496.05M-136.11M364%
Gain YTD12.861-32.619-39%
P/E RatioN/AN/A-
Revenue03.96M-
Total Cash837M28.6M2,927%
Total Debt52.5M5.75M913%
FUNDAMENTALS RATINGS
DNLI vs PGEN: Fundamental Ratings
DNLI
PGEN
OUTLOOK RATING
1..100
638
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
57
Fair valued
PROFIT vs RISK RATING
1..100
85100
SMR RATING
1..100
9498
PRICE GROWTH RATING
1..100
4884
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
n/a11

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PGEN's Valuation (57) in the null industry is somewhat better than the same rating for DNLI (94) in the Biotechnology industry. This means that PGEN’s stock grew somewhat faster than DNLI’s over the last 12 months.

DNLI's Profit vs Risk Rating (85) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that DNLI’s stock grew similarly to PGEN’s over the last 12 months.

DNLI's SMR Rating (94) in the Biotechnology industry is in the same range as PGEN (98) in the null industry. This means that DNLI’s stock grew similarly to PGEN’s over the last 12 months.

DNLI's Price Growth Rating (48) in the Biotechnology industry is somewhat better than the same rating for PGEN (84) in the null industry. This means that DNLI’s stock grew somewhat faster than PGEN’s over the last 12 months.

DNLI's P/E Growth Rating (99) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that DNLI’s stock grew similarly to PGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIPGEN
RSI
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 1 day ago
83%
Declines
ODDS (%)
Bearish Trend 4 days ago
78%
Bearish Trend 4 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
86%
Aroon
ODDS (%)
Bullish Trend 1 day ago
72%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MLPRX4.880.08
+1.67%
Invesco SteelPath MLP Income C
RREAX29.630.13
+0.44%
Russell Inv Global Real Estate Secs A
AFCGX17.280.07
+0.41%
American Century Focused Intl Gr G
CICAX61.760.17
+0.28%
American Funds Invmt Co of Amer 529A
JCAVX10.39N/A
N/A
JHFunds2 Capital Appreciation Value NAV

PGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PGEN has been loosely correlated with CRSP. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if PGEN jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PGEN
1D Price
Change %
PGEN100%
+7.91%
CRSP - PGEN
55%
Loosely correlated
-2.05%
NTLA - PGEN
53%
Loosely correlated
+5.18%
BEAM - PGEN
52%
Loosely correlated
-3.72%
DNLI - PGEN
51%
Loosely correlated
-0.82%
RCKT - PGEN
50%
Loosely correlated
-1.92%
More